Shares of 10x Genomics, Inc. (NASDAQ:TXG – Get Free Report) have received a consensus rating of “Hold” from the seventeen analysts that are currently covering the company, Ratings reports. One ...

Briefly, FASTQ files were uploaded to Cell Ranger (10X Genomics cloud), and no depth normalization was carried out. The generated filtered count matrix was further analyzed using the Seurat package in ...

Single-cell transcriptomics has revolutionized the study of cellular diversity and function by enabling gene expression ...

The chart above depicts the trend in analyst earnings per share (EPS) forecasts for 10X Genomics Inc for the upcoming quarter. Analysts have reduced this quarter's expectations by -81.2% for EPS from ...

A growing leader in the diagnostics space, Nucleus Genomics expands access to genetic screening and testing beyond what patients may be able to get from their regular healthcare providers. The company ...

A growing leader in the diagnostics space, Nucleus Genomics expands access to genetic screening and testing beyond what patients may be able to get from their regular healthcare providers.

Genetic testing can be critical to ensuring the early diagnosis and proper treatment of serious disease for patients of all ages The partnership combines Ubie's AI-driven symptom identification ...

PLEASANTON, Calif., Feb. 23, 2025 /PRNewswire/ -- At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology ...